

[HIV Home](#)

Core Indicators for Monitoring the Ending the HIV Epidemic Initiative (*Preliminary Data*):

National HIV Surveillance System Data Reported through March 2023; and Preexposure Prophylaxis (PrEP) Data Reported through December 2022

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through March 2023 and preexposure prophylaxis (PrEP) data reported through December 2022.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested Citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through March 2023; and preexposure prophylaxis (PrEP) data reported through December 2022. *HIV Surveillance Data Tables* 2023;4(2). <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>. Published June 2023. Accessed [date].

On the Web: <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>

Confidential information, referrals, and educational material on HIV infection

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

Acknowledgments

HIV Surveillance Data Tables was prepared by the following staff and contractors of the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Ya-lin Huang, Weiming Zhu, Emily Zhu, Pei Hou, Chelsea Walker, Chan Jin, Thanh Chau Pham, Sue Reynolds, Lei Yu, Avery Smithson, Wei Wei, Iddrisu Abdallah, Norma Harris, Stacy Cohen, and Michael Friend (editing).

The Web and Consumer Services Team of the Prevention Communications Branch are acknowledged for their contributions to the report website.

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

Technical Notes



The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and then by at least 90% by 2030. The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core Indicators for Monitoring the Ending the HIV Epidemic Initiative* report at <https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-1-no-1/cdc-hiv-surveillance-tables-vol-1-no-1.pdf>.

The tables included in this report provide *preliminary* data on HIV diagnoses for the years 2022 and 2023 and linkage to HIV medical care for the year 2022 based on cases reported to CDC as of March 2023. Data on preexposure prophylaxis (PrEP) coverage are provided for the years 2019, 2020, 2021, and 2022 (preliminary). Data for the 3 indicators are provided at the national, state, and county levels (EHE Phase I jurisdictions only). See *Tabulation and Presentation of Data* for details on how the indicators are calculated.

Tabulation and Presentation of Data

Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged ≥ 13 years with HIV diagnosed during January 2022 through March 2023 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2016–2020 diagnoses) found that, on average, approximately 80% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 98% of HIV diagnoses are reported to CDC by the end of the following year. Data for years 2022 and 2023 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting diagnoses of HIV infection can be found in the *HIV Surveillance Report, 2021* at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-34/index.html>.

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥ 13 years whose infection was diagnosed during the year 2022 and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed during the year 2022 and who had ≥ 1 CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed during the year 2022. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons whose HIV infection was diagnosed during the year 2022 and reported to NHSS through March 2023. Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

More information on calculating linkage to care can be found in *Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2021* at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-28-no-4/index.html>.

Preexposure Prophylaxis (PrEP) Coverage

PrEP coverage, reported as a percentage, is defined as the number of persons aged ≥ 16 years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged ≥ 16 years who had indications for PrEP during the specified year (Tables 3a–c). PrEP coverage is an EHE indicator that is not a reportable disease or condition and is not reported to NHSS. Multiple data sources, described below, are used to calculate PrEP coverage. Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage. Please note that changes in the total percentage across each report are because data are received at multiple points through the year; readers should note the period for which the data are calculated and use caution when comparing partial year data to full year data.

Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

Persons prescribed PrEP

National pharmacy data from the IQVIA Real World Data—Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged ≥ 16 years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 93% of all prescriptions from retail pharmacies and 77% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [2–4]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the U.S. Food and Drug Administration (FDA) in October 2019. Long-acting injectable cabotegravir (CAB-LA) was approved by the FDA as an additional prevention option for PrEP in December 2021. After the respective approvals, TAF/FTC and CAB-LA were included in the algorithm to classify the number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database, and race/ethnicity data are available for <40% of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA database include White, Black/African American, Hispanic/Latino, and other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

Geographic Designations

In the IQVIA database, a person's location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [5], and (b) the U.S. Department of Housing and Urban Development's ZIP Code Crosswalk Files [6]. Because of reliability concerns, subnational estimates of <40 are not included.

Persons with PrEP indications

U.S. Census Bureau files and their ACS were used to estimate the number of gay, bisexual, and other men who have sex with men (MSM) in a jurisdiction [7, 8]. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [9].

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [7]. Jurisdictional estimates were rounded to the nearest 10.

The tables included in this report provide updated data on PrEP coverage for the years 2019–2022 by using the IQVIA data reported through December 2022. IQVIA conducts data quality assurance activities. As a result, the number of persons classified as having been prescribed PrEP in a given year might change from time to time. The impact of the changes may vary by demographic category nationally and by jurisdiction. The data sources used to estimate the number of persons with indications for PrEP have different schedules of availability. Consequently, the availability of a denominator lags the availability of a numerator. PrEP coverage data with a lagged denominator are considered preliminary.

For this release of HIV Surveillance Data Tables, 2018 denominators were used for 2019, 2020, 2021, and 2022 PrEP coverage data; consequently, 2019 through 2022 PrEP coverage data are considered preliminary. In addition to being preliminary, data for the year 2020 should be interpreted with awareness of the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions [10].

More information on calculating PrEP coverage can be found in *Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2021* at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>.

References







1. HHS. What is *Ending the HIV Epidemic in the U.S.*? <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>  . Updated July 2, 2022. Accessed June 7, 2023.
2. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014  . *Clin Infect Dis* 2017;64(2):144–149. doi:10.1093/cid/ciw701
3. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. *MMWR* 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3
4. Furukawa NW, Smith DK, Gonzalez CJ, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016–June 2018  . *Public Health Rep* 2020;135(2):202–210. doi:10.1177/0033354920904085
5. U.S. Census Bureau. American Community Survey 5-year data (2009–2021). <https://www.census.gov/data/developers/data-sets/acs-5year.2019.html>  . Published March 2022. Accessed June 7, 2023.
6. U.S. Department of Housing and Urban Development (HUD). HUD USPS ZIP code crosswalk files. https://www.huduser.gov/portal/datasets/usps_crosswalk.html  . Updated August 2022. Accessed June 7, 2023.
7. Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey  . *JMIR Public Health Surveill* 2016;2(1):e14. doi:10.2196/publichealth.5365
8. Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates  . *Open AIDS J* 2012;6:98–107. doi:10.2174/1874613601206010098
9. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. *MMWR* 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4
10. Huang YA, Zhu W, Wiener J, Kourtis AP, Hall HI, Hoover KW. Impact of COVID-19 on HIV preexposure prophylaxis prescriptions in the United States—a time series analysis  . *Clin Infect Dis* 2022:ciac038. doi:10.1093/cid/ciac038

Table 1a. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2022 through March 2023—United States (preliminary) 

	2022	2023 (January–March)
	No.	No.
Gender		
Male	29,047	4,857
Female	6,794	1,153
Transgender woman ^a	755	76
Transgender man ^a	50	9
Additional gender identity ^b	58	6
Age at diagnosis (yr)		
13–24	6,722	1,011
25–34	13,690	2,180
35–44	8,100	1,444
45–54	4,485	801
≥ 55	3,707	665
Race/ethnicity		
American Indian/Alaska Native	210	21
Asian	787	121
Black/African American	14,500	2,556
Hispanic/Latino ^c	11,347	1,730
Native Hawaiian/other Pacific Islander	77	9
White	8,990	1,572
Multiracial	793	92
Transmission category^d		
Male-to-male sexual contact ^e	24,779	4,102
Injection drug use ^f		
Male	1,395	226
Female	1,151	160
Male-to-male sexual contact ^e and injection drug use ^f	1,219	177
Heterosexual contact ^g		
Male	2,423	426
Female	5,614	991
Other ^h		
Male	40	8
Female	83	11
Region of residence		
Northeast	4,975	621
Midwest	4,786	880
South	19,800	3,722
West	7,143	878
Total	36,704	6,101

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through March 2023. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender.

“Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^bAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^cHispanic/Latino persons can be of any race.


^dTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^eIncludes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

^fIncludes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^gHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.

^hOther risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 1b. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2022 through March 2023—United States and 6 dependent areas (preliminary) 

	2022	2023 (January–March)
	No.	No.
Gender		
Male	29,340	4,896
Female	6,854	1,162
Transgender woman ^a	757	76
Transgender man ^a	50	9
Additional gender identity ^b	58	6
Age at diagnosis (yr)		
13–24	6,769	1,013
25–34	13,808	2,196
35–44	8,169	1,454
45–54	4,549	814
≥ 55	3,764	672
Race/ethnicity		
American Indian/Alaska Native	210	21
Asian	787	121
Black/African American	14,504	2,557
Hispanic/Latino ^c	11,691	1,774
Native Hawaiian/other Pacific Islander	77	9
White	8,997	1,574
Multiracial	793	93
Transmission category^d		
Male-to-male sexual contact ^e	24,995	4,128
Injection drug use ^f		
Male	1,420	228
Female	1,157	160
Male-to-male sexual contact ^e and injection drug use ^f	1,224	177

	2022	2023 (January–March)
	No.	No.
Heterosexual contact^g		
Male	2,472	437
Female	5,667	999
Other^h		
Male	41	8
Female	84	12
Region of residence		
Northeast	4,975	621
Midwest	4,786	880
South	19,800	3,722
West	7,143	878
U.S. dependent areas	355	48
Total	37,059	6,149

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through March 2023. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender.

“Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^bAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^cHispanic/Latino persons can be of any race.


^dTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^eIncludes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

^fIncludes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^gHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.

^hOther risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 1c. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2022 through March 2023—United States and 6 dependent areas (preliminary) 

Area of residence	2022	2023 (January–March)
	No.	No.
Alabama	404	57
Alaska	35	4
Arizona	845	2
Arkansas	312	79
California	4,182	487
Colorado	427	68
Connecticut	220	23
Delaware	127	25
District of Columbia	183	3

Area of residence	2022	2023 (January–March)
	No.	No.
Florida	4,872	1,238
Georgia	2,532	427
Hawaii	65	4
Idaho	44	2
Illinois	1,223	122
Indiana	620	95
Iowa	118	36
Kansas	135	34
Kentucky	406	89
Louisiana	884	193
Maine	40	6
Maryland	742	108
Massachusetts	391	4
Michigan	637	165
Minnesota	261	58
Mississippi	408	55
Missouri	507	103
Montana	10	5
Nebraska	89	13
Nevada	535	103
New Hampshire	27	4
New Jersey	1,101	109
New Mexico	75	3
New York	2,199	337
North Carolina	1,373	303
North Dakota	10	1
Ohio	859	182
Oklahoma	336	40
Oregon	247	57
Pennsylvania	931	138
Rhode Island	62	0
South Carolina	793	175
South Dakota	39	8
Tennessee	850	183
Texas	4,600	561
Utah	137	15
Vermont	4	0
Virginia	838	169
Washington	527	127
West Virginia	140	17
Wisconsin	288	63
Wyoming	14	1
Subtotal	36,704	6,101
U.S. dependent areas		
American Samoa	0	0

Area of residence	2022	2023 (January–March)
	No.	No.
Guam	0	0
Northern Mariana Islands	0	0
Puerto Rico	345	45
Republic of Palau	0	0
U.S. Virgin Islands	10	3
Subtotal	355	48
Total	37,059	6,149

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at the time of diagnosis of HIV infection. Data are for cases reported to CDC through March 2023. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 1d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2022 through March 2023—Ending the HIV Epidemic Phase I jurisdictions (preliminary)

Area of residence	2022	2023 (January–March)
	No.	No.
Arizona		
Maricopa County	557	0
California		
Alameda County	200	35
Los Angeles County	1,303	142
Orange County	250	48
Riverside County	273	25
Sacramento County	134	0
San Bernardino County	250	12
San Diego County	279	24
San Francisco County	213	39
District of Columbia	183	3
Florida		
Broward County	638	174
Duval County	310	69
Hillsborough County	335	90
Miami-Dade County	1,140	323
Orange County	471	94
Palm Beach County	348	58
Pinellas County	134	43
Georgia		
Cobb County	162	35
DeKalb County	380	56
Fulton County	584	104
Gwinnett County	157	28
Illinois		
Cook County	810	77

Area of residence	2022	2023 (January–March)
	No.	No.
Indiana		
Marion County	249	30
Louisiana		
East Baton Rouge Parish	132	29
Orleans Parish	129	28
Maryland		
Baltimore City	154	22
Montgomery County	111	14
Prince George's County	247	27
Massachusetts		
Suffolk County	108	3
Michigan		
Wayne County	246	72
Nevada		
Clark County	487	94
New Jersey		
Essex County	234	11
Hudson County	174	13
New York		
Bronx County	399	49
Kings County	475	63
New York County	320	44
Queens County	365	49
North Carolina		
Mecklenburg County	281	77
Ohio		
Cuyahoga County	121	33
Franklin County	192	47
Hamilton County	94	17
Pennsylvania		
Philadelphia County	365	67
Puerto Rico		
San Juan Municipio	107	15
Tennessee		
Shelby County	338	75
Texas		
Bexar County	303	6
Dallas County	864	122
Harris County	1,238	191
Tarrant County	320	31
Travis County	234	35
Washington		
King County	277	60

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at the time of diagnosis of HIV infection. Data are for cases reported to CDC through March 2023. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis during 2022 among persons aged ≥ 13 years, by selected characteristics—47 states and the District of Columbia (preliminary)

	Total diagnoses	≥ 1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
Gender					
Male	27,412	22,622	82.5	4,790	17.5
Female	6,385	5,146	80.6	1,239	19.4
Transgender woman ^a	727	610	83.9	117	16.1
Transgender man ^a	47	43	91.5	4	8.5
Additional gender identity ^b	57	54	94.7	3	5.3
Age at diagnosis (yr)					
13–24	6,408	5,192	81.0	1,216	19.0
25–34	12,876	10,562	82.0	2,314	18.0
35–44	7,609	6,292	82.7	1,317	17.3
45–54	4,245	3,510	82.7	735	17.3
≥ 55	3,490	2,919	83.6	571	16.4
Race/ethnicity					
American Indian/Alaska Native	205	161	78.5	44	21.5
Asian	747	665	89.0	82	11.0
Black/African American	13,758	10,864	79.0	2,894	21.0
Hispanic/Latino ^c	10,616	9,101	85.7	1,515	14.3
Native Hawaiian/other Pacific Islander	76	57	75.0	19	25.0
White	8,496	7,018	82.6	1,478	17.4
Multiracial	730	609	83.4	121	16.6
Transmission category^d					
Male-to-male sexual contact ^e	23,514	19,541	83.1	3,973	16.9
Injection drug use ^f	2,328	1,782	76.6	545	23.4
Male	1,259	959	76.1	301	23.9
Female	1,069	824	77.1	245	22.9
Male-to-male sexual contact ^e and injection drug use ^f	1,157	951	82.2	206	17.8
Heterosexual contact ^g	7,516	6,104	81.2	1,412	18.8
Male	2,226	1,803	81.0	423	19.0
Female	5,290	4,301	81.3	989	18.7
Total^h	34,628	28,475	82.2	6,153	17.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥ 1 CD4 or VL tests ≤ 1 month after diagnosis of HIV infection. Data are for cases reported to CDC through March 2023, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are based on residence at time of diagnosis of HIV infection. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender.

“Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^bAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^cHispanic/Latino persons can be of any race.

^dTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^eIncludes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

^fIncludes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^gHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.

^hIncludes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.


Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis during 2022 among persons ^haged ≥13 years, by area of residence—47 states and the District of Columbia (preliminary)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
Alabama	404	329	81.4	75	18.6
Alaska	35	31	88.6	4	11.4
Arizona	845	712	84.3	133	15.7
Arkansas	312	256	82.1	56	17.9
California	4,182	3,495	83.6	687	16.4
Colorado	427	359	84.1	68	15.9
Connecticut	220	184	83.6	36	16.4
Delaware	127	105	82.7	22	17.3
District of Columbia	183	161	88.0	22	12.0
Florida	4,872	4,076	83.7	796	16.3
Georgia	2,532	2,121	83.8	411	16.2
Hawaii	65	55	84.6	10	15.4
Illinois	1,223	1,030	84.2	193	15.8
Indiana	620	470	75.8	150	24.2
Iowa	118	109	92.4	9	7.6
Kansas	135	120	88.9	15	11.1
Kentucky	406	316	77.8	90	22.2
Louisiana	884	709	80.2	175	19.8
Maine	40	36	90.0	4	10.0
Maryland	742	651	87.7	91	12.3
Massachusetts	391	342	87.5	49	12.5
Michigan	637	549	86.2	88	13.8
Minnesota	261	225	86.2	36	13.8
Mississippi	408	218	53.4	190	46.6
Missouri	507	411	81.1	96	18.9
Montana	10	7	70.0	3	30.0
Nebraska	89	76	85.4	13	14.6
Nevada	535	476	89.0	59	11.0

Area of residence	Total diagnoses		≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	
New Hampshire	27	20	74.1	7	25.9	
New Mexico	75	68	90.7	7	9.3	
New York	2,199	1,923	87.4	276	12.6	
North Carolina	1,373	1,107	80.6	266	19.4	
North Dakota	10	7	70.0	3	30.0	
Ohio	859	705	82.1	154	17.9	
Oklahoma	336	266	79.2	70	20.8	
Oregon	247	207	83.8	40	16.2	
Rhode Island	62	58	93.5	4	6.5	
South Carolina	793	631	79.6	162	20.4	
South Dakota	39	27	69.2	12	30.8	
Tennessee	850	602	70.8	248	29.2	
Texas	4,600	3,601	78.3	999	21.7	
Utah	137	112	81.8	25	18.2	
Vermont	4	4	100.0	0	0.0	
Virginia	838	688	82.1	150	17.9	
Washington	527	463	87.9	64	12.1	
West Virginia	140	87	62.1	53	37.9	
Wisconsin	288	258	89.6	30	10.4	
Wyoming	14	12	85.7	2	14.3	

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥ 1 CD4 or VL tests ≤ 1 month after diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through March 2023, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis during 2022 among persons ≥ 13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) 

Area of residence	Total diagnoses		≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	
Arizona						
Maricopa County	557	473	84.9	84	15.1	
California						
Alameda County	200	175	87.5	25	12.5	
Los Angeles County	1,303	1,073	82.3	230	17.7	
Orange County	250	213	85.2	37	14.8	
Riverside County	273	218	79.9	55	20.1	
Sacramento County	134	118	88.1	16	11.9	
San Bernardino County	250	178	71.2	72	28.8	
San Diego County	279	237	84.9	42	15.1	

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
San Francisco County	213	195	91.5	18	8.5
District of Columbia	183	161	88.0	22	12.0
Florida					
Broward County	638	523	82.0	115	18.0
Duval County	310	230	74.2	80	25.8
Hillsborough County	335	281	83.9	54	16.1
Miami-Dade County	1,140	955	83.8	185	16.2
Orange County	471	386	82.0	85	18.0
Palm Beach County	348	310	89.1	38	10.9
Pinellas County	134	116	86.6	18	13.4
Georgia					
Cobb County	162	135	83.3	27	16.7
DeKalb County	380	319	83.9	61	16.1
Fulton County	584	490	83.9	94	16.1
Gwinnett County	157	137	87.3	20	12.7
Illinois					
Cook County	810	689	85.1	121	14.9
Indiana					
Marion County	249	194	77.9	55	22.1
Louisiana					
East Baton Rouge Parish	132	113	85.6	19	14.4
Orleans Parish	129	109	84.5	20	15.5
Maryland					
Baltimore City	154	135	87.7	19	12.3
Montgomery County	111	97	87.4	14	12.6
Prince George's County	247	221	89.5	26	10.5
Massachusetts					
Suffolk County	108	97	89.8	11	10.2
Michigan					
Wayne County	246	205	83.3	41	16.7
Nevada					
Clark County	487	433	88.9	54	11.1
New York					
Bronx County	399	340	85.2	59	14.8
Kings County	475	426	89.7	49	10.3
New York County	320	268	83.8	52	16.3
Queens County	365	326	89.3	39	10.7
North Carolina					
Mecklenburg County	281	226	80.4	55	19.6
Ohio					
Cuyahoga County	121	102	84.3	19	15.7
Franklin County	192	160	83.3	32	16.7
Hamilton County	94	81	86.2	13	13.8
Pennsylvania					
Philadelphia County	365	297	81.4	68	18.6

Area of residence	Total diagnoses		≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	
Tennessee						
Shelby County	338	218	64.5	120	35.5	
Texas						
Bexar County	303	240	79.2	63	20.8	
Dallas County	864	650	75.2	214	24.8	
Harris County	1,238	967	78.1	271	21.9	
Tarrant County	320	238	74.4	82	25.6	
Travis County	234	204	87.2	30	12.8	
Washington						
King County	277	251	90.6	26	9.4	

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥ 1 CD4 or VL tests ≤ 1 month after diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through March 2023, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2022, among persons aged ≥ 16 years, by selected characteristics—United States

	2019			2020 (COVID-19 pandemic)			2021			2022	
	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b
	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.
Sex at birth											
Male	253,749	989,200	25.7	276,883	989,200	28.0	337,625	989,200	34.1	404,742	989,200
Female	21,030	227,010	9.3	23,559	227,010	10.4	28,012	227,010	12.3	32,801	227,010
Age (yr)											
16–24	37,607	246,290	15.3	37,736	246,290	15.3	48,581	246,290	19.7	57,351	246,290
25–34	111,700	434,680	25.7	120,256	434,680	27.7	145,805	434,680	33.5	173,643	434,680
35–44	64,063	238,470	26.9	71,857	238,470	30.1	88,542	238,470	37.1	108,472	238,470
45–54	37,412	173,420	21.6	40,468	173,420	23.3	46,253	173,420	26.7	53,130	173,420
≥ 55	24,141	123,350	19.6	30,192	123,350	24.5	36,739	123,350	29.8	45,070	123,350
Race/ethnicity^d											
Black/African American	37,286	468,540	8.0	43,288	468,540	9.2	51,766	468,540	11.0	60,003	468,540
Hispanic/Latino ^e	45,379	312,820	14.5	51,259	312,820	16.4	63,938	312,820	20.4	76,410	312,820
Other	12,234	131,180	9.3	12,788	131,180	9.7	15,710	131,180	12.0	19,100	131,180
White	180,024	300,650	59.9	193,174	300,650	64.3	234,504	300,650	78.0	282,153	300,650
Total	274,922	1,216,210	22.6	300,509	1,216,210	24.7	365,919	1,216,210	30.1	437,666	1,216,210

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through December 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

^b Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2019–2022 PrEP coverage data.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Race/ethnicity data were only available for <40% of persons prescribed PrEP each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

^e Hispanic/Latino persons can be of any race.

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2022, among persons aged ≥16 years, by area of residence—United States and Puerto Rico

Area of residence	2019			2020 (COVID-19 pandemic)			2021			2022	
	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indication
	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.
Alabama	1,834	11,020	16.6	1,904	11,020	17.3	2,759	11,020	25.0	3,437	11,020
Alaska	226	1,780	12.7	241	1,780	13.5	307	1,780	17.2	403	1,780
Arizona	4,570	25,780	17.7	5,052	25,780	19.6	6,565	25,780	25.5	8,346	25,780
Arkansas	726	5,130	14.2	861	5,130	16.8	1,272	5,130	24.8	1,673	5,130
California	41,597	165,030	25.2	42,248	165,030	25.6	50,272	165,030	30.5	61,641	165,030
Colorado	4,399	25,120	17.5	4,794	25,120	19.1	6,188	25,120	24.6	7,611	25,120
Connecticut	2,664	9,560	27.9	2,461	9,560	25.7	3,040	9,560	31.8	4,001	9,560
Delaware	482	4,400	11.0	478	4,400	10.9	649	4,400	14.8	834	4,400
District of Columbia	5,892	12,950	45.5	5,981	12,950	46.2	6,797	12,950	52.5	7,686	12,950
Florida	21,781	125,330	17.4	34,530	125,330	27.6	42,619	125,330	34.0	46,428	125,330
Georgia	8,638	39,030	22.1	9,748	39,030	25.0	12,160	39,030	31.2	13,728	39,030
Hawaii	813	4,360	18.6	899	4,360	20.6	1,131	4,360	25.9	1,505	4,360
Idaho	479	4,790	10.0	665	4,790	13.9	880	4,790	18.4	1,075	4,790
Illinois	16,635	55,860	29.8	15,961	55,860	28.6	18,411	55,860	33.0	21,925	55,860
Indiana	2,979	22,170	13.4	3,189	22,170	14.4	4,246	22,170	19.2	5,465	22,170
Iowa	1,409	4,760	29.6	1,551	4,760	32.6	1,949	4,760	40.9	2,202	4,760
Kansas	900	5,060	17.8	949	5,060	18.8	1,277	5,060	25.2	1,605	5,060
Kentucky	1,605	12,990	12.4	1,659	12,990	12.8	2,224	12,990	17.1	3,034	12,990
Louisiana	3,911	15,920	24.6	3,566	15,920	22.4	4,149	15,920	26.1	4,744	15,920
Maine	650	3,950	16.5	668	3,950	16.9	904	3,950	22.9	1,126	3,950

Area of residence	2019			2020 (COVID-19 pandemic)			2021			2022	
	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indication
	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.
Maryland	4,916	27,300	18.0	4,790	27,300	17.5	5,793	27,300	21.2	6,892	27,300
Massachusetts	9,298	24,900	37.3	9,367	24,900	37.6	10,146	24,900	40.7	13,002	24,900
Michigan	4,341	29,570	14.7	4,656	29,570	15.7	5,890	29,570	19.9	7,161	29,570
Minnesota	4,199	21,720	19.3	4,200	21,720	19.3	5,251	21,720	24.2	6,578	21,720
Mississippi	948	4,530	20.9	1,092	4,530	24.1	1,593	4,530	35.2	1,732	4,530
Missouri	3,466	18,370	18.9	3,560	18,370	19.4	4,162	18,370	22.7	5,133	18,370
Montana	267	2,290	11.7	292	2,290	12.8	393	2,290	17.2	535	2,290
Nebraska	618	2,180	28.3	714	2,180	32.8	1,000	2,180	45.9	1,274	2,180
Nevada	2,185	11,390	19.2	2,503	11,390	22.0	4,874	11,390	42.8	5,677	11,390
New Hampshire	617	3,020	20.4	645	3,020	21.4	798	3,020	26.4	1,039	3,020
New Jersey	5,664	25,280	22.4	5,892	25,280	23.3	7,259	25,280	28.7	8,925	25,280
New Mexico	1,072	6,800	15.8	1,234	6,800	18.1	1,595	6,800	23.5	2,036	6,800
New York	35,314	72,640	48.6	34,137	72,640	47.0	39,103	72,640	53.8	45,803	72,640
North Carolina	5,396	32,490	16.6	6,151	32,490	18.9	7,951	32,490	24.5	9,990	32,490
North Dakota	187	1,520	12.3	183	1,520	12.0	246	1,520	16.2	337	1,520
Ohio	6,084	40,320	15.1	6,795	40,320	16.9	8,453	40,320	21.0	10,330	40,320
Oklahoma	1,161	11,030	10.5	1,531	11,030	13.9	2,321	11,030	21.0	2,781	11,030
Oregon	3,396	19,750	17.2	3,821	19,750	19.3	4,687	19,750	23.7	6,062	19,750
Pennsylvania	10,082	36,490	27.6	10,555	36,490	28.9	13,039	36,490	35.7	16,060	36,490
Puerto Rico	329	9,700	3.4	370	9,700	3.8	609	9,700	6.3	818	9,700
Rhode Island	1,087	3,880	28.0	1,158	3,880	29.8	1,516	3,880	39.1	1,824	3,880
South Carolina	1,723	10,390	16.6	2,099	10,390	20.2	2,929	10,390	28.2	3,657	10,390
South Dakota	150	910	16.5	141	910	15.5	216	910	23.7	321	910
Tennessee	3,891	22,460	17.3	5,163	22,460	23.0	7,227	22,460	32.2	8,871	22,460
Texas	23,124	123,790	18.7	27,501	123,790	22.2	34,730	123,790	28.1	40,698	123,790
Utah	2,037	6,840	29.8	2,366	6,840	34.6	3,256	6,840	47.6	4,023	6,840
Vermont	337	1,060	31.8	322	1,060	30.4	480	1,060	45.3	574	1,060
Virginia	4,404	31,430	14.0	5,121	31,430	16.3	6,281	31,430	20.0	7,579	31,430
Washington	9,892	40,050	24.7	10,072	40,050	25.1	11,377	40,050	28.4	13,738	40,050
West Virginia	567	5,250	10.8	521	5,250	9.9	707	5,250	13.5	912	5,250
Wisconsin	2,474	12,980	19.1	2,532	12,980	19.5	2,820	12,980	21.7	3,347	12,980
Wyoming	96	890	10.8	98	890	11.0	138	890	15.5	186	890

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].


Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through December 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

^b Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018

denominators were used for 2019–2022 PrEP coverage data.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2022, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions 

	2019			2020 (COVID-19 pandemic)			2021			2022	
	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^t
	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.
Arizona											
Maricopa County	3,529	22,720	15.5	3,893	22,720	17.1	5,025	22,720	22.1	6,411	22,720
California											
Alameda County	2,159	8,930	24.2	2,016	8,930	22.6	2,210	8,930	24.7	2,708	8,930
Los Angeles County	13,692	67,450	20.3	14,718	67,450	21.8	18,471	67,450	27.4	23,388	67,450
Orange County	2,031	10,510	19.3	2,190	10,510	20.8	2,826	10,510	26.9	3,333	10,510
Riverside County	1,805	11,080	16.3	1,943	11,080	17.5	2,546	11,080	23.0	3,220	11,080
Sacramento County	952	5,920	16.1	974	5,920	16.5	1,102	5,920	18.6	1,365	5,920
San Bernardino County	756	11,890	6.4	814	11,890	6.8	1,191	11,890	10.0	1,553	11,890
San Diego County	3,724	14,500	25.7	3,798	14,500	26.2	4,432	14,500	30.6	5,380	14,500
San Francisco County	8,826	10,840	81.4	8,136	10,840	75.1	8,202	10,840	75.7	9,068	10,840
District of Columbia	5,892	12,950	45.5	5,981	12,950	46.2	6,797	12,950	52.5	7,686	12,950
Florida											
Broward County	3,839	20,470	18.8	6,786	20,470	33.2	8,347	20,470	40.8	8,065	20,470
Duval County	494	8,970	5.5	717	8,970	8.0	878	8,970	9.8	1,507	8,970
Hillsborough County	1,388	12,910	10.8	1,533	12,910	11.9	2,053	12,910	15.9	2,624	12,910
Miami-Dade County	6,470	21,760	29.7	10,202	21,760	46.9	11,411	21,760	52.4	11,256	21,760
Orange County	2,787	15,310	18.2	3,895	15,310	25.4	4,736	15,310	30.9	5,828	15,310
Palm Beach County	885	9,170	9.7	3,004	9,170	32.8	2,749	9,170	30.0	2,450	9,170
Pinellas County	1,146	9,530	12.0	1,232	9,530	12.9	1,662	9,530	17.4	2,120	9,530
Georgia											

	2019			2020 (COVID-19 pandemic)			2021			2022	
	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^t
	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.
Cobb County	569	3,070	18.5	657	3,070	21.4	813	3,070	26.5	924	3,070
DeKalb County	1,539	6,290	24.5	1,681	6,290	26.7	2,016	6,290	32.1	2,223	6,290
Fulton County	3,295	13,120	25.1	3,590	13,120	27.4	4,269	13,120	32.5	4,671	13,120
Gwinnett County	687	3,240	21.2	798	3,240	24.6	1,003	3,240	31.0	1,144	3,240
Illinois											
Cook County	13,617	39,060	34.9	12,891	39,060	33.0	14,764	39,060	37.8	17,247	39,060
Indiana											
Marion County	1,150	9,150	12.6	1,212	9,150	13.2	1,584	9,150	17.3	1,997	9,150
Louisiana											
East Baton Rouge Parish	491	1,810	27.1	532	1,810	29.4	587	1,810	32.4	616	1,810
Orleans Parish	1,510	4,590	32.9	1,328	4,590	28.9	1,518	4,590	33.1	1,674	4,590
Maryland											
Baltimore City	900	6,330	14.2	840	6,330	13.3	973	6,330	15.4	1,131	6,330
Montgomery County	893	5,770	15.5	896	5,770	15.5	1,153	5,770	20.0	1,458	5,770
Prince George's County	792	4,040	19.6	816	4,040	20.2	982	4,040	24.3	1,088	4,040
Massachusetts											
Suffolk County	2,763	6,520	42.4	2,799	6,520	42.9	2,807	6,520	43.1	3,590	6,520
Michigan											
Wayne County	1,200	9,270	12.9	1,226	9,270	13.2	1,547	9,270	16.7	1,867	9,270
Nevada											
Clark County	1,864	11,670	16.0	2,102	11,670	18.0	4,282	11,670	36.7	4,345	11,670
New Jersey											
Essex County	678	4,090	16.6	709	4,090	17.3	836	4,090	20.4	1,010	4,090
Hudson County	1,061	4,650	22.8	1,065	4,650	22.9	1,296	4,650	27.9	1,602	4,650
New York											
Bronx County	2,201	5,570	39.5	2,026	5,570	36.4	2,081	5,570	37.4	2,127	5,570
Kings County	7,595	15,650	48.5	7,431	15,650	47.5	8,889	15,650	56.8	10,414	15,650
New York County	14,148	15,540	91.0	13,746	15,540	88.5	15,753	15,540	101.4	18,072	15,540
Queens County	3,860	9,230	41.8	3,801	9,230	41.2	4,283	9,230	46.4	5,208	9,230
North Carolina											

	2019			2020 (COVID-19 pandemic)			2021			2022	
	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b
	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.
Mecklenburg County	1,340	8,450	15.9	1,580	8,450	18.7	1,968	8,450	23.3	2,339	8,450
Ohio											
Cuyahoga County	947	7,520	12.6	958	7,520	12.7	1,258	7,520	16.7	1,675	7,520
Franklin County	2,035	11,620	17.5	2,301	11,620	19.8	2,733	11,620	23.5	3,111	11,620
Hamilton County	560	7,720	7.3	635	7,720	8.2	814	7,720	10.5	982	7,720
Pennsylvania											
Philadelphia County	3,651	9,840	37.1	3,507	9,840	35.6	4,056	9,840	41.2	4,996	9,840
Puerto Rico											
San Juan Municipio	25	2,190	1.1	28	2,190	1.3	64	2,190	2.9	117	2,190
Tennessee											
Shelby County	637	6,450	9.9	816	6,450	12.7	945	6,450	14.7	1,166	6,450
Texas											
Bexar County	1,531	11,920	12.8	1,779	11,920	14.9	2,353	11,920	19.7	2,859	11,920
Dallas County	4,098	28,670	14.3	5,156	28,670	18.0	6,556	28,670	22.9	7,205	28,670
Harris County	4,935	40,670	12.1	5,986	40,670	14.7	7,479	40,670	18.4	8,679	40,670
Tarrant County	1,454	11,340	12.8	1,634	11,340	14.4	2,104	11,340	18.6	2,499	11,340
Travis County	4,511	11,590	38.9	5,029	11,590	43.4	5,765	11,590	49.7	6,575	11,590
Washington											
King County	6,892	17,890	38.5	6,965	17,890	38.9	7,628	17,890	42.6	8,993	17,890

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through December 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

^b Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2019–2022 PrEP coverage data.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Table 4. Ending the HIV Epidemic Phase I jurisdictions




Jurisdictions	Territories	States
---------------	-------------	--------

Jurisdictions	Territories	States
<p><i>Arizona</i></p> <ul style="list-style-type: none"> • Maricopa County <p><i>California</i></p> <ul style="list-style-type: none"> • Alameda County • Los Angeles County • Orange County • Riverside County • Sacramento County • San Bernardino County • San Diego County • San Francisco County <p><i>District of Columbia</i></p> <p><i>Florida</i></p> <ul style="list-style-type: none"> • Broward County • Duval County • Hillsborough County • Miami-Dade County • Orange County • Palm Beach County • Pinellas County <p><i>Georgia</i></p> <ul style="list-style-type: none"> • Cobb County • DeKalb County • Fulton County • Gwinnett County <p><i>Illinois</i></p> <ul style="list-style-type: none"> • Cook County <p><i>Indiana</i></p> <ul style="list-style-type: none"> • Marion County <p><i>Louisiana</i></p> <ul style="list-style-type: none"> • East Baton Rouge Parish • Orleans Parish <p><i>Maryland</i></p> <ul style="list-style-type: none"> • Baltimore City • Montgomery County • Prince George's County <p><i>Massachusetts</i></p> <ul style="list-style-type: none"> • Suffolk County <p><i>Michigan</i></p> <ul style="list-style-type: none"> • Wayne County <p><i>Nevada</i></p>	<p><i>Puerto Rico</i>^a</p> <ul style="list-style-type: none"> • San Juan Municipio^a 	<p>Alabama</p> <p>Arkansas</p> <p>Kentucky</p> <p>Mississippi</p> <p>Missouri</p> <p>Oklahoma</p> <p>South Carolina</p>

Jurisdictions	Territories	States
<ul style="list-style-type: none"> Clark County <p><i>New Jersey^a</i></p> <ul style="list-style-type: none"> Essex County Hudson County <p><i>New York</i></p> <ul style="list-style-type: none"> Bronx County Kings County New York County Queens County <p><i>North Carolina</i></p> <ul style="list-style-type: none"> Mecklenburg County <p><i>Ohio</i></p> <ul style="list-style-type: none"> Cuyahoga County Franklin County Hamilton County <p><i>Pennsylvania^a</i></p> <ul style="list-style-type: none"> Philadelphia County <p><i>Tennessee</i></p> <ul style="list-style-type: none"> Shelby County <p><i>Texas</i></p> <ul style="list-style-type: none"> Bexar County Dallas County Harris County Tarrant County Travis County <p><i>Washington</i></p> <ul style="list-style-type: none"> King County 		

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview> .

^a Linkage to care and viral suppression data are not provided for states and associated jurisdictions that have incomplete reporting of laboratory data to CDC: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

Last Reviewed: June 23, 2023